PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer

Author:

Wang Kai,Yan Lili,Qiu Xun,Chen Huan,Gao Fengqiang,Ge Wenwen,Lian Zhengxing,Wei Xuyong,Wang Shuai,He Hong,Xu Xiao

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

Publisher

Elsevier BV

Reference41 articles.

1. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2020

2. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: a nationwide pancreas data center analysis, Chin;Hu;J. Cancer Res. Ther.,2021

3. Pancreatic cancer;Mizrahi;Lancet,2020

4. Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis;Damm;Cancers (Basel),2021

5. Advances in early diagnosis and therapy of pancreatic cancer;Xu;Hepatobiliary Pancreat. Dis. Int.,2011

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3